Lavipharm: Investments and acquisitions drive growth and international expansion

Lavipharm Group recorded a 24.1% increase in consolidated sales before clawbacks and rebates, while EBITDA from continuing operations rose by 5.2% in the first half of 2026. The results confirm… Lavipharm: Investments and acquisitions drive growth and international expansion - Η…

To respect copyright, we link to the source rather than republishing the full text. Read the complete article on Naftemporiki.